Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Non-Current Deffered Revenue: 2017-2024

Historic Non-Current Deffered Revenue for Protagonist Therapeutics (PTGX) over the last 4 years, with Dec 2024 value amounting to $11.7 million.

  • Protagonist Therapeutics' Non-Current Deffered Revenue fell 83.11% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year decrease of 83.11%. This contributed to the annual value of $11.7 million for FY2024, which is N/A change from last year.
  • As of FY2024, Protagonist Therapeutics' Non-Current Deffered Revenue stood at $11.7 million, which was down 50.92% from $23.8 million recorded in FY2019.
  • In the past 5 years, Protagonist Therapeutics' Non-Current Deffered Revenue ranged from a high of $11.7 million in FY2024 and a low of $11.7 million during FY2024.
  • In the last 1 years, Protagonist Therapeutics' Non-Current Deffered Revenue had a median value of $11.7 million in 2024 and averaged $11.7 million.